scholarly journals AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016

Breast Care ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. 216-222 ◽  
Author(s):  
Marc Thill ◽  
Cornelia Liedtke ◽  
Breast Care ◽  
2021 ◽  
pp. 1-8
Author(s):  
Marc Thill ◽  
Michael Friedrich ◽  
Cornelia Kolberg-Liedtke ◽  
Ute-Susann Albert ◽  
Maggie Banys-Paluchowski ◽  
...  

Breast Care ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. 247-255 ◽  
Author(s):  
Marc Thill ◽  
Christian Jackisch ◽  
Wolfgang Janni ◽  
Volkmar Müller ◽  
Ute-Susann Albert ◽  
...  

Every year the Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO), a group of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiologic diagnostics, medical oncology, and radiation oncology, prepares and updates evidence-based recommendations for the diagnosis and treatment of patients with early and metastatic breast cancer. Every update is performed according to a documented rule-fixed algorithm, by thoroughly reviewing and scoring the recent publications for their scientific validity and clinical relevance. This current publication presents the 2019 update on the recommendations for metastatic breast cancer.


Breast Care ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. 202-209 ◽  
Author(s):  
Volker Hanf ◽  
Florian Schütz ◽  
Cornelia Liedtke ◽  
Marc Thill

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 231s-231s
Author(s):  
L.H.d.C. Barros ◽  
M. Kruse ◽  
N.S.F. Rosa ◽  
R.A. Kaliks ◽  
J.C. Dalri

Background: Globally, it is estimated there will be a 43% increase in breast cancer-related deaths from 2015 to 2030, largely as a result of cancer metastasis. Metastatic breast cancer (mBC) is the most advanced stage of breast cancer where the cancer has spread from the original site to other parts of the body. While resources are available for early detection of breast cancer, there is a lack of information and support for those with an advanced breast cancer diagnosis in Brazil. To address this need, Instituto Oncoguia developed the National Metastatic Breast Cancer Patient Support Network, the “More Life Network.” This research is part of the Network initiative and seeks to increase knowledge and support for patients living with mBC. Aim: The aim of this study is to examine the mBC patient journey through diagnosis, treatment and quality of life after diagnosis. Methods: In May 2018, we conducted a cross-sectional study of mBC patients in Brazil. Patients were recruited voluntarily through online platforms. A quantitative online survey instrument was used for data collection. Frequency analysis was conducted across the main subject areas: knowledge, diagnosis, treatment, and quality of life. Results: A total of 188 online surveys were included in the analysis. Participants represent 20 of 26 states in Brazil and have a mean age of 44. Of the 188 participants, 114 are members of the Network. Knowledge about mBC was assessed through patient self-reporting. Approximately one third of patients (32%) reported little to no knowledge of mBC. When a patient does have questions about their diagnosis and treatment, a majority (83%) seek information from their physician. The Network was also indicated as a resource referenced by patients (51%). To understand the cancer journey, questions focused on diagnosis, treatment, and quality of life. Twenty-two percent (22%) of patients stated the most complicated or longest step of their journey was identifying symptoms of metastasis. The process of diagnosis was challenging, as well. Thirty-six percent (36%) of patients reported their metastasis was an incidental (by chance) diagnosis and 30% had little or insufficient information about the possibility of metastasis. After diagnosis, only 17% of patients continued working, while 78% worked prior to diagnosis. During treatment, the greatest hurdles in the patient journey include a decline in quality of life (42%) and lack of understanding or access to information about mBC (31%). The life of the patient is also impacted after diagnosis and treatment. Sixty-eight percent (68%) of patients expressed fear of the future and 61% felt they could no longer do the activities they previously enjoyed. Conclusion: This research demonstrates the lack of available information specific to a mBC diagnosis and the need for additional support throughout the cancer journey for patients living with mBC. Current breast cancer resources do not adequately address these challenges.


2021 ◽  
Vol 22 (4) ◽  
pp. 47-55
Author(s):  
Irina V. Poddubnaya ◽  
Joseph Gligorov ◽  
Liudmila G. Zhukova ◽  
Elena I. Kovalenko ◽  
M. A. Frolova

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer was held on 16th October 2020. The French and Russian oncology experts shared information and exchanged experience concerning the application of the first PI3K inhibitor alpelisib.


Breast Care ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. 294-309 ◽  
Author(s):  
Nina Ditsch ◽  
Michael Untch ◽  
Cornelia Kolberg-Liedtke ◽  
Christian Jackisch ◽  
David Krug ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document